Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63-KH for Prevention of Post-kala Azar Dermal Leishmaniasis
NCT04107961Phase 2Withdrawn
- Sponsor
- University of York
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Viral Vector Vaccines
01
Overview
Phase 2, randomised, double-blind trial of ChAd63-KH in Post kala-azar dermal leishmaniasis (PKDL) (2 arms), sponsored by University of York. Primary endpoints: Safety of single dose vaccination with ChAd63-KH at 12 months and Efficacy of single dose vaccination with ChAd63-KH at 12 months. Planned start Oct 2023; status: withdrawn.
02
Drugs
ChAd63-KH
03
Conditions
Post kala-azar dermal leishmaniasis (PKDL)
Beyond the preview
Go deeper on NCT04107961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04107961.